ALTERED ADENYLYL-CYCLASE ACTIVITIES AND G-PROTEIN ABNORMALITIES IN PORTAL HYPERTENSIVE RABBITS

被引:42
作者
CAHILL, PA
WU, YP
SITZMANN, JV
机构
[1] Johns Hopkins Medical Institutions, Department of Surgery, Baltimore
[2] Johns Hopkins Hospital, Department of Surgery, Baltimore, MD 21287-4665, Blalock 665
关键词
G-PROTEIN; ADENYLYL CYCLASE; PORTAL HYPERTENSION; PORTAL BLOOD FLOW; MESENTERIC BLOOD FLOW;
D O I
10.1172/JCI117283
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Portal hypertension(PHT) is characterized by splanchnic hyperemia due to a reduction in mesenteric vascular resistance. We hypothesized that alterations in the activity of a guanine-nucleotide regulatory protein (G-protein) might be partially responsible for the marked circulatory disturbances observed in PHT. We, therefore, determined alterations in adenylyl cyclase/cAMP system in prehepatic portal hypertensive rabbits and correlated these changes to the activity of a G-protein. Basal and G-protein-stimulated adenylyl cyclase activities were lower in the PHT superior mesenteric artery (22-26%) and thoracic aorta (31-46%) membranes, but higher (178-321%) in portal vein. The functional activity of Gi alpha proteins (pertussis toxin-catalyzed ADP-dependent ribosylation) increased in the PHT superior mesenteric artery and thoracic aorta, but decreased in portal vein. Immunodetection revealed an increase in the Gi alpha protein subunits(Gi alpha 1/Gi alpha 2 and Gi alpha 3/ G0 alpha) in PHT thoracic aorta, without any change in Gs alpha proteins; and a decrease in the amount of Gi alpha proteins in PHT portal vein. There was no change in the amount of Gs alpha/Gi alpha in the PHT superior mesenteric artery. We conclude the hemodynamic alterations of PHT are associated with intrinsic alterations in G-protein-enzyme effector systems. These alterations are vessel specific and suggest a possible unique global derangement underlying the vasculopathy of PHT.
引用
收藏
页码:2691 / 2700
页数:10
相关论文
共 35 条
[1]   HEPATIC CIRCULATION - POTENTIAL FOR THERAPEUTIC INTERVENTION [J].
BALLET, F .
PHARMACOLOGY & THERAPEUTICS, 1990, 47 (02) :281-328
[2]   ROLE OF GLUCAGON IN SPLANCHNIC HYPEREMIA OF CHRONIC PORTAL-HYPERTENSION [J].
BENOIT, JN ;
ZIMMERMAN, B ;
PREMEN, AJ ;
GO, VLW ;
GRANGER, DN .
AMERICAN JOURNAL OF PHYSIOLOGY, 1986, 251 (05) :G674-G677
[3]  
BOHM M, 1992, J HYPERTENS, V10, P1115
[4]  
BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
[5]  
BRODDE OE, 1992, J HYPERTENS, V10, pS133
[6]   NITRIC-OXIDE SYNTHASE ACTIVITY IN PORTAL-HYPERTENSION [J].
CAHILL, PA ;
WU, YP ;
SITZMANN, JV .
HEPATOLOGY, 1993, 18 (04) :A141-A141
[7]  
CECH SY, 1980, MOL CELL BIOCHEM, V33, P67
[8]   HYPERSENSITIVITY OF MESENTERIC VEINS TO 5-HYDROXYTRYPTAMINE-INDUCED AND KETANSERIN-INDUCED REDUCTION OF PORTAL PRESSURE IN PORTAL HYPERTENSIVE RATS [J].
CUMMINGS, SA ;
GROSZMANN, RJ ;
KAUMANN, AJ .
BRITISH JOURNAL OF PHARMACOLOGY, 1986, 89 (03) :501-513
[9]   INHIBITION OF CATALYTIC UNIT OF ADENYLATE-CYCLASE AND ACTIVATION OF GTPASE OF NI PROTEIN BY BETA-GAMMA-SUBUNITS OF GTP-BINDING PROTEINS [J].
ENOMOTO, K ;
ASAKAWA, T .
FEBS LETTERS, 1986, 202 (01) :63-68
[10]  
ESCHENHAGEN T, 1992, MOL PHARMACOL, V42, P773